Skip to main content
FinSpry Logo
FinSpry
RNXT logo
RNXT
(NASDAQ)
RenovoRx, Inc.
$0.85-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

RenovoRx (RNXT) Company Profile

Complete business overview, executive team, trading details, and corporate information.

RenovoRx, Inc.
RNXT•Nasdaq Stock Market•Healthcare•Biotechnology

About RenovoRx

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOShaun Bagai
Founded2012
IPO DateAugust 26, 2021
Employees17
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websiterenovorx.com
Phone650 284 4433
Address
2570 West El Camino Real, Suite 320 Mountain View, California 94040 United States

Corporate Identifiers

CIK0001574094
CUSIP75989R107
ISINUS75989R1077
EIN27-1448452
SIC2834

Leadership Team & Key Executives

Shaun R. Bagai
Chief Executive Officer, Secretary and Director
Dr. Ramtin Agah M.D.
Founder, Executive Chairman and Chief Medical Officer
Ronald B. Kocak CPA, CGMA
Vice President of Finance and Controller
Mark Voll
Chief Financial Officer and Principal Accounting Officer
Robert Strasser
Vice President of Operations and Research & Development
Leesa Gentry
Chief Clinical Officer
Ryan Witt
Senior Vice President and Head of Corporate Strategy and Partnerships